R1 Therapeutics competitors & alternatives

Unicycive Therapeutics, Inc.UNCY · BiotechLos Altos, United States

70% matchPublic

Biotech

Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.

RAPTBiotechnologyUnited States

70% match

Biotechnology

RAPT Therapeutics is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2015, the public company leverages its proprietary drug discovery platform to develop treatments for inflammatory and immunologic diseases.

XORTX Therapeutics Inc.XRTX · BiotechnologyCalgary, Canada

70% matchPublic

Biotechnology

XORTX Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney diseases, including specific pipeline candidates for gout and other conditions.

Biotech

ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.

Enyo PharmaBiotechFrance

70% match

Biotech

ENYO Pharma is a clinical-stage biopharmaceutical company that develops therapeutics for patients with impaired kidney function. Its lead compound, Vonafexor, is a small molecule currently in Phase 2 development to treat rare kidney diseases such as Alport syndrome and chronic kidney disease.

Biotechnology

Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.

Relation Therapeutics Inc.BiotechUnited States

67% matchPrivateAI 83/100Green 0/100

Biotech

Relation Therapeutics Inc. is an active for-profit biotechnology company founded in 2019 that focuses on therapeutic development.

Rakuten MedicalBiotechUnited States

67% matchPrivate

Biotech

Rakuten Medical, Inc. is a global biotechnology company headquartered in San Diego, California, that develops precision, cell-targeting investigational therapies using its proprietary Alluminox technology platform.

Ambros TherapeuticsBiotechnologyUnited States

67% match

Biotechnology

Ambros Therapeutics is a clinical-stage biotechnology company headquartered in Irvine, California, focused on the development of innovative therapeutics.

Circle Pharma, Inc.BiotechnologyUnited States

66% matchPrivate

Biotechnology

Circle Pharma, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, harnessing macrocycles for drug development.

Biotech

Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.

RallybioRLYB · BiotechnologyNew Haven, United States

66% matchPublic

Biotechnology

Rallybio is a clinical-stage biotechnology company that develops therapies for patients with severe and rare diseases, focusing on areas such as complement dysregulation and hematology. The company's pipeline includes therapeutic assets like C5 inhibitors designed to address significant unmet medical needs.